FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224141531> ?p ?o ?g. }

• W4224141531 endingPage "785" @default.
• W4224141531 startingPage "776" @default.
• W4224141531 abstract "To examine the safety and efficacy of microwave tissue coagulation (MTC) for prostate cancer and assess its use in lesion-targeted focal therapy in a non-clinical study and a clinical phase II trial.In the non-clinical study using Microtaze® -AFM-712 (Alfresa Pharma Corporation, Osaka, Japan) with an MTC needle, MTC was performed using a transperineal approach to targeted canine prostatic tissue under real-time ultrasonography guidance. Using various MTC output and irradiation time combinations, the targeted and surrounding tissues (rectum, bladder and fat) were examined to confirm the extent of coagulative necrosis or potential cell death, and to compare intra-operative ultrasonography and pathology findings. The exploratory clinical trial was conducted to examine the safety and efficacy of MTC. Five selected patients underwent transperineal MTC to clinically single lesion magnetic resonance imaging (MRI)-visible lesions with Gleason score 3 + 4 or 4 + 4. Prostate-specific antigen (PSA), MRI and Expanded Prostate Cancer Index Composite questionnaire findings were compared before and 6 months after surgery.The region of coagulative necrosis was predictable by monitoring of ultrasonically visible vaporization; thus, by placing the MTC needle at a certain distance, we were able to perform a safe procedure without adverse events affecting the surrounding organs. Based on the non-clinical study, which used various combinations of output and irradiation time, MTC with 30-W output for 60-s irradiation was selected for the prostate. Based on the predictable necrosis, the therapeutic plan (where to place the MTC needle to achieve complete ablation of the target and how many sessions) was strictly determined per patient. There were no serious adverse events in any patient and only temporary urinary symptoms related to MTC therapy were observed. Furthermore, post-treatment satisfaction was very high. All preoperative MRI-visible lesions disappeared, and PSA decreased by 55% 6 months after surgery.Microwave tissue coagulation may be an option for lesion-targeted focal therapy for prostate cancer." @default.
• W4224141531 created "2022-04-20" @default.
• W4224141531 creator A5001092101 @default.
• W4224141531 creator A5002366300 @default.
• W4224141531 creator A5002937255 @default.
• W4224141531 creator A5014879465 @default.
• W4224141531 creator A5016215778 @default.
• W4224141531 creator A5020491175 @default.
• W4224141531 creator A5032428362 @default.
• W4224141531 creator A5033402616 @default.
• W4224141531 creator A5038502946 @default.
• W4224141531 creator A5040656434 @default.
• W4224141531 creator A5041964655 @default.
• W4224141531 creator A5060919162 @default.
• W4224141531 creator A5063799912 @default.
• W4224141531 creator A5065661141 @default.
• W4224141531 creator A5067052630 @default.
• W4224141531 creator A5082127173 @default.
• W4224141531 creator A5083496309 @default.
• W4224141531 creator A5086795397 @default.
• W4224141531 creator A5088381952 @default.
• W4224141531 date "2022-05-26" @default.
• W4224141531 modified "2023-09-27" @default.
• W4224141531 title "Microwave focal therapy of prostate cancer: a non‐clinical study and exploratory clinical trial" @default.
• W4224141531 cites W1963749208 @default.
• W4224141531 cites W1982311990 @default.
• W4224141531 cites W1995589176 @default.
• W4224141531 cites W1997096707 @default.
• W4224141531 cites W2055996215 @default.
• W4224141531 cites W2057282689 @default.
• W4224141531 cites W2076962939 @default.
• W4224141531 cites W2094825887 @default.
• W4224141531 cites W2129034112 @default.
• W4224141531 cites W2137282952 @default.
• W4224141531 cites W2138302361 @default.
• W4224141531 cites W2138925586 @default.
• W4224141531 cites W2143962930 @default.
• W4224141531 cites W2519027667 @default.
• W4224141531 cites W2616037983 @default.
• W4224141531 cites W2735211627 @default.
• W4224141531 cites W2768699815 @default.
• W4224141531 cites W2784041986 @default.
• W4224141531 cites W2902102041 @default.
• W4224141531 cites W2922071185 @default.
• W4224141531 cites W2979462020 @default.
• W4224141531 cites W2987849399 @default.
• W4224141531 cites W3030952566 @default.
• W4224141531 cites W3096071679 @default.
• W4224141531 cites W3181702891 @default.
• W4224141531 doi "https://doi.org/10.1111/bju.15749" @default.
• W4224141531 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35434902" @default.
• W4224141531 hasPublicationYear "2022" @default.
• W4224141531 type Work @default.
• W4224141531 citedByCount "4" @default.
• W4224141531 countsByYear W42241415312022 @default.
• W4224141531 crossrefType "journal-article" @default.
• W4224141531 hasAuthorship W4224141531A5001092101 @default.
• W4224141531 hasAuthorship W4224141531A5002366300 @default.
• W4224141531 hasAuthorship W4224141531A5002937255 @default.
• W4224141531 hasAuthorship W4224141531A5014879465 @default.
• W4224141531 hasAuthorship W4224141531A5016215778 @default.
• W4224141531 hasAuthorship W4224141531A5020491175 @default.
• W4224141531 hasAuthorship W4224141531A5032428362 @default.
• W4224141531 hasAuthorship W4224141531A5033402616 @default.
• W4224141531 hasAuthorship W4224141531A5038502946 @default.
• W4224141531 hasAuthorship W4224141531A5040656434 @default.
• W4224141531 hasAuthorship W4224141531A5041964655 @default.
• W4224141531 hasAuthorship W4224141531A5060919162 @default.
• W4224141531 hasAuthorship W4224141531A5063799912 @default.
• W4224141531 hasAuthorship W4224141531A5065661141 @default.
• W4224141531 hasAuthorship W4224141531A5067052630 @default.
• W4224141531 hasAuthorship W4224141531A5082127173 @default.
• W4224141531 hasAuthorship W4224141531A5083496309 @default.
• W4224141531 hasAuthorship W4224141531A5086795397 @default.
• W4224141531 hasAuthorship W4224141531A5088381952 @default.
• W4224141531 hasConcept C121608353 @default.
• W4224141531 hasConcept C126322002 @default.
• W4224141531 hasConcept C126838900 @default.
• W4224141531 hasConcept C126894567 @default.
• W4224141531 hasConcept C142724271 @default.
• W4224141531 hasConcept C143409427 @default.
• W4224141531 hasConcept C197934379 @default.
• W4224141531 hasConcept C21613296 @default.
• W4224141531 hasConcept C2776235491 @default.
• W4224141531 hasConcept C2780192828 @default.
• W4224141531 hasConcept C535046627 @default.
• W4224141531 hasConcept C71924100 @default.
• W4224141531 hasConceptScore W4224141531C121608353 @default.
• W4224141531 hasConceptScore W4224141531C126322002 @default.
• W4224141531 hasConceptScore W4224141531C126838900 @default.
• W4224141531 hasConceptScore W4224141531C126894567 @default.
• W4224141531 hasConceptScore W4224141531C142724271 @default.
• W4224141531 hasConceptScore W4224141531C143409427 @default.
• W4224141531 hasConceptScore W4224141531C197934379 @default.
• W4224141531 hasConceptScore W4224141531C21613296 @default.
• W4224141531 hasConceptScore W4224141531C2776235491 @default.
• W4224141531 hasConceptScore W4224141531C2780192828 @default.
• W4224141531 hasConceptScore W4224141531C535046627 @default.

• next